Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program.
Aronora, Inc., a clinical-stage biotech poised to revolutionize blood clot treatment and prevention, today announced it has closed an investment from NYBC Ventures, a venture fund established by New York Blood Center.
Aronora Secures Investment From New York Blood Center Read More »
ReAlta Life Sciences was pleased to welcome Senator Mark R. Warner (D-Va) for an in-depth visit with the ReAlta management team, members of the ReAlta board of directors, and local investors on October 2, 2023.
ValGenesis, Inc. and Brevitas, an independent technology consulting firm, have partnered to introduce the ValGenesis product suite alongside Brevitas’ immense technical expertise in life sciences across the US and Canada.
ValGenesis and Brevitas Announce Strategic Partnership Read More »
Eli Lilly and Company announced that mirikizumab met the co-primary and all major secondary endpoints compared to placebo in VIVID-1, a Phase 3 study evaluating the safety and efficacy of mirikizumab for the treatment of adults with moderately to severely active Crohn’s disease.
Escient Pharmaceuticals announced that the first subject has been dosed in CALM-CSU, a Phase 2 clinical proof-of-concept study of EP262 in subjects with chronic spontaneous urticaria.
So-Young International Inc., the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, announced that Mr. Min Yu, Mr. Xuejian Li, Mr. Charles Zhaoxuan Yang and Mr. Harry Jiannan Wang have tendered their resignations as directors of the Company for personal reasons, effective as of
So-Young Announces Board Change – October 12, 2023 Read More »
West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that it will release third-quarter 2023 financial results before the market opens on Thursday, October 26, 2023, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.
Genentech, a member of the Roche Group, announced new clinical and real-world data for Ocrevus® demonstrating its role in continuing to transform care for people living with relapsing or primary progressive multiple sclerosis presented at the 9th Joint ECTRIMS-ACTRIMS Meeting.
Neoss Group, a leading innovator in dental implant solutions, is proud to announce that it has received EU Medical Device Regulation certification by its Notified Body, the BSI Group, the Netherlands B.V. for its implants and abutments.
